These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18683068)

  • 1. Clinical efficacy of two different drug combinations for the treatment of canine leishmaniasis.
    Pennisi MG; Lo Giudice S; Masucci M; De Majo M; Reale S; Vitale F
    Vet Res Commun; 2008 Sep; 32 Suppl 1():S303-5. PubMed ID: 18683068
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of antimonial therapy for canine leishmaniasis on antibody titer.
    Amusategui I; Sainz A; Tesouro MA
    Ann N Y Acad Sci; 1998 Jun; 849():444-6. PubMed ID: 9668509
    [No Abstract]   [Full Text] [Related]  

  • 3. Some remarks about the LeishVet directions for the treatment of canine leishmaniasis.
    Lamothe J
    Vet Parasitol; 2010 May; 169(3-4):416-7; author reply 418-20. PubMed ID: 20106598
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis.
    Oliva G; Gradoni L; Cortese L; Orsini S; Ciaramella P; Scalone A; de Luna R; Persechino A
    Ann Trop Med Parasitol; 1998 Mar; 92(2):165-71. PubMed ID: 9625912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
    Carrió J; Portús M
    BMC Pharmacol; 2002 May; 2():11. PubMed ID: 12019027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of meglumine antimoniate in canine leishmaniasis.
    Lamothe J
    Vet Rec; 2004 Mar; 154(12):378. PubMed ID: 15074332
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.
    Mateo M; Maynard L; Vischer C; Bianciardi P; Miró G
    Parasitol Res; 2009 Jul; 105(1):155-62. PubMed ID: 19238439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of the treatment of dogs with leishmaniosis with a combination of metronidazole and spiramycin.
    Pennisi MG; De Majo M; Masucci M; Britti D; Vitale F; Del Maso R
    Vet Rec; 2005 Mar; 156(11):346-9. PubMed ID: 15789648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Canine leishmaniasis chemotherapy: dog's clinical condition and risk of Leishmania transmission.
    João A; Pereira MA; Cortes S; Santos-Gomes GM
    J Vet Med A Physiol Pathol Clin Med; 2006 Dec; 53(10):540-5. PubMed ID: 17105576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring the reverse to normal of clinico-pathological findings and the disease free interval time using four different treatment protocols for canine leishmaniosis in an endemic area.
    Paradies P; Sasanelli M; Amato ME; Greco B; De Palo P; Lubas G
    Res Vet Sci; 2012 Oct; 93(2):843-7. PubMed ID: 22296941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol.
    Torres M; Bardagí M; Roura X; Zanna G; Ravera I; Ferrer L
    Vet J; 2011 Jun; 188(3):346-51. PubMed ID: 20594876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of serum albumin/globulin ratio after antimonial therapy in canine leishmaniasis.
    Amusategui I; Sainz A; Tesouro MA
    Ann N Y Acad Sci; 1998 Jun; 849():447-9. PubMed ID: 9668510
    [No Abstract]   [Full Text] [Related]  

  • 13. Real-time PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol.
    Manna L; Reale S; Vitale F; Picillo E; Pavone LM; Gravino AE
    Vet J; 2008 Aug; 177(2):279-82. PubMed ID: 17553711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulomatous lesion on a bitch's nipple caused by Leishmania infantum.
    Gómez-Ochoa P; Gascón M; Aceña MC; Miana-Mena FJ; Castillo JA
    Vet Rec; 2005 Mar; 156(12):389. PubMed ID: 15816188
    [No Abstract]   [Full Text] [Related]  

  • 15. Hair parasite load as a new biomarker for monitoring treatment response in canine leishmaniasis.
    Corpas-López V; Merino-Espinosa G; Acedo-Sánchez C; Díaz-Sáez V; Morillas-Márquez F; Martín-Sánchez J
    Vet Parasitol; 2016 Jun; 223():20-5. PubMed ID: 27198771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment.
    Gramiccia M; Gradoni L; Orsini S
    Ann Trop Med Parasitol; 1992 Dec; 86(6):613-20. PubMed ID: 1304703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of leishmanial osteolytic lesions in a hypothyroid dog by partial tarsal arthrodesis.
    Franch J; Pastor J; Torrent E; Lafuente P; Diaz-Bertrana MC; Munilla A; Durall I
    Vet Rec; 2004 Oct; 155(18):559-62. PubMed ID: 15559422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis.
    Guarga JL; Moreno J; Lucientes J; Gracia MJ; Peribáñez MA; Castillo JA
    Vet Immunol Immunopathol; 2002 Sep; 88(1-2):13-20. PubMed ID: 12088640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on canine leishmaniasis control. 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment.
    Mancianti F; Gramiccia M; Gradoni L; Pieri S
    Trans R Soc Trop Med Hyg; 1988; 82(4):566-7. PubMed ID: 3076714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of Western blotting in the clinical follow-up of canine leishmaniasis.
    Fernández-Pérez FJ; Méndez S; de la Fuente C; Cuquerella M; Gómez MT; Alunda JM
    J Vet Diagn Invest; 1999 Mar; 11(2):170-3. PubMed ID: 10098690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.